Last reviewed · How we verify
NCT04942431: RAS2
REBIRTH Active School 2.0 . a School Based Physical Activity Program
NA trial testing Rebirth active SCHOOL 2.0 movement program in Primary School Children in 1,245 participants. Participants enrolled and being followed up; not accepting new ones.
30 July 2025
Quick facts
| Lead sponsor | Hannover Medical School |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 1,245 |
| Start date | 28 June 2021 |
| Primary completion | 30 July 2025 |
| Estimated completion | 30 December 2025 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Rebirth active SCHOOL 2.0 movement program
Conditions studied
- Primary School Children — all drugs for Primary School Children →
Sponsor
Hannover Medical School
Who can join
Adults 6 to 12, any sex, with Primary School Children. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Rebirth active SCHOOL 2.0 is a physical activity intervention program and about to be realised at 40 primary schools in Lower Saxony Germany. Half of all schools will be assigned to the intervention program or to wait for one year before starting with the movement program. After one and two years, the follow up will take place. After completing baseline examinations (i.e. physical and cognitive functions, physical activity questionnaires) the intervention program will start for one year. The intervention program is going to be designed with the goal of implementing physical activity of 60 minutes per day. For the main module of movement impulses, the pupils will perform a 5-minute exercise in every lesson, realised by the teachers.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Strategies for enhancing the implementation of school-based policies or practices targeting diet, physical activity, obesity, tobacco or alcohol use.
Lee DC, O'Brien KM, McCrabb S, Wolfenden L, et al · · 2024 · cited 11× · PMID 39665378 · DOI 10.1002/14651858.cd011677.pub4
Verify or expand the search:
- PubMed search for NCT04942431
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Hannover Medical School trials
Trials by the same sponsor.
- NCT07384039 — Exercise Training in Patients With Myeloproliferative Neoplasms · NA · not yet recruiting
- NCT06740747 — Intermittent Theta-Burst Stimulation to Improve Negative Symptoms and Cognition in Schizophrenia · NA · recruiting
- NCT06795516 — Observational Study on the Clinical Use of ex Vivo Lung Perfusion (XPS™) for Lung Transplantation · terminated
- NCT06603311 — Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of · NA · active not recruiting
- NCT06493006 — Promoting Sustainable and Active Mobility Among Employees and Students · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04942431 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hannover Medical School
- Last refreshed: 11 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04942431.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing